Subject and method: A cross-sectional study, follow-up for 12 weeks, comparing before and after treatment on 124 patients with type 2 diabetes, outpatient treatment at 108 Military Central Hospital from 12/2021 to 4/2022, with HbA1c level 7% - 10%, on at least 1 OAD previous, supplemented with dapagliflozin 10mg.